Literature DB >> 6214598

Gentamicin nephrotoxicity. I. Degree and permanence of acquired insensitivity.

W C Elliott, D C Houghton, D N Gilbert, J Baines-Hunter, W M Bennett.   

Abstract

Insensitivity to the nephrotoxic effects of gentamicin develops in F344 rats during the course of gentamicin-mediated acute renal failure. Functional and structural recovery occur thereafter in spite of continued gentamicin administration. To determine the degree of insensitivity, we compared structural and functional recovery of rats treated continuously with gentamicin to rats in which gentamicin was stopped after 14 days, at the height of dysfunction. Continued treatment did not reduce the rate or ultimate degree of recovery of structure, CIn, or in vitro renal cortical PAH uptake; however, both the rate and degree of recovery of NMN uptake were reduced in continuously treated animals. Furthermore, doubling the dose of gentamicin during the recovery period overcame insensitivity, causing a second episode of acute renal failure. The permanence of insensitivity was examined by re-treating rats 6 months after recovery from gentamicin-mediated acute renal failure. There was no evidence of residual resistance to gentamicin nephrotoxicity in these animals. These results indicate that although gentamicin insensitivity is substantial, it is not complete, as indicated by low-grade, ongoing tubular toxicity to the organic base transport system and sensitivity to higher doses of gentamicin. Furthermore, insensitivity is a transient phenomenon.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214598

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  12 in total

1.  Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme oxygenase-dependent resistance to renal injury.

Authors:  B A Vogt; T P Shanley; A Croatt; J Alam; K J Johnson; K A Nath
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Aberrant tubuloglomerular feedback and HIF-1α confer resistance to ischemia after subtotal nephrectomy.

Authors:  Prabhleen Singh; Roland C Blantz; Christian Rosenberger; Francis B Gabbai; Trenton R Schoeb; Scott C Thomson
Journal:  J Am Soc Nephrol       Date:  2012-01-19       Impact factor: 10.121

3.  Acquired cytoresistance in the setting of hematopoietic cell transplantation.

Authors:  Richard A Zager
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-21       Impact factor: 8.237

4.  Aminoglycoside nephrotoxicity: modeling, simulation, and control.

Authors:  Florent Rougier; Daniel Claude; Michel Maurin; Alexandre Sedoglavic; Michel Ducher; Stéphane Corvaisier; Roger Jelliffe; Pascal Maire
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Potentiated nephrotoxicity of cisplatin when combined with amikacin comparing young and adult rats.

Authors:  H T Jongejan; A P Provoost; J C Molenaar
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

6.  Decreased cellular toxicity of neomycin in a clonal cell line isolated from LLC-PK1.

Authors:  R Hori; M Okuda; Y Ohishi; M Yasuhara; K Inui; M Takano
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

7.  Effect of some simple manoeuvres on the course of acute renal failure after gentamycin treatment in rats.

Authors:  J Heller
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

8.  Endotoxin mediates recruitment of RNA polymerase II to target genes in acute renal failure.

Authors:  Masayo Naito; Karol Bomsztyk; Richard A Zager
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

9.  Potentiation of cis-diamminedichloroplatinum nephrotoxicity by amikacin in rats.

Authors:  H T Jongejan; A P Provoost; J C Molenaar
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Chronic gentamicin nephrotoxicity. Continued tubular injury with preserved glomerular filtration function.

Authors:  D C Houghton; D Lee; D N Gilbert; W M Bennett
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.